Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 4306
Licensor hereby grants to Licensee, and Licensee accepts, an exclusive, license to use Licensor's â€œEpoSafeâ€ and â€œMedisulfoneâ€ marks and variations of same in the Territory solely in conjunction with the sale and distribution of the Products.
Under the License and Supply Agreement, the Licensor granted to the Licensee an exclusive License, with right of sublicense, to market, promote, distribute, offer for sale and sell the Filtration Products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement.
In addition, the Licensee granted to the Italian Licensor an exclusive License under the Licensee's intellectual property to make the Filtration Products during the term of the License and Supply Agreement.
Licensor offers several MedisulfoneÂ® membranes, one of which is dedicated to blood filtration treatments like hemofiltration and hemoconcentration, while the other provides excellent performances in the ultra-filtration of water requiring high purity fluids for medical use and drinkable water.
An additional advantage of Medisulfone is that it can be disinfected by using chlorine or peracetic acid compounds or the most common disinfecting agents in the dialysis field making for versatility and practicality.
The Licensee has been engaged primarily in the development of hemodiafiltration, or HDF, products and technologies for treating patients with End Stage Renal Disease, or ESRD.
IPSCIO Record ID: 215500
Licensor manufactures a proprietary hollow fiber polysulfone synthetic membrane for blood and water purification in medical and industrial applications.
The Company has two products in the hemodiafiltration (â€œHDFâ€) modality to deliver therapy for ESRD patients. These are the OLpur mid-dilution HDF filter or â€œdialyzer,â€ designed expressly for HDF therapy, and the OLpur H2H HDF module, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy.
ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as 'middle molecules.' These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products, which includes the MSU and SSU ultrafilters. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins.
IPSCIO Record ID: 367343
Method and System for Colloid Exchange Therapy;
Hemofiltration Systems, Methods and Devices Used to Treat Inflammatory Mediator Related Disease;
Hemofiltration Systems, Methods, and Devices Used for Treatment of Chronic and Acute Diseases; and,
Method and System for Colloid Exchange Therapy.